Novo Nordisk, the largest European company by market capitalization, has achieved worse than expected results for its new slimming drug CagriSema ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

The White House on Friday said Novo Nordisk’s weight-loss drugs Wegovy and Ozempic were among the 15 medications picked for a ...

GLP-1 drugs used for weight loss involve all kinds of side effects—good and not-so-good—that may or may not strike the ...

In the ongoing quest to expand semaglutide’s clinical pedigree and cement the GLP-1's market position, Novo Nordisk is ...

Announcement of the 15 medicines chosen for the second round of negotiations is one of the Biden administration’s final ...

In one corner, we’ve got Mounjaro, and in the other, Ozempic. They’re both once-a-week injectable drugs designed to help ...

Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...